Efficacy and Safety of a Once‐Yearly Intravenous Zoledronic Acid 5 mg for Fracture Prevention in Elderly Postmenopausal Women with Osteoporosis Aged 75 and Older
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: To determine the efficacy of once‐yearly intravenous zoledronic acid (ZOL) 5 mg in reducing risk of clinical vertebral, nonvertebral, and any clinical fractures in elderly osteoporotic postmenopausal women. DESIGN: A post hoc subgroup analysis of pooled data from the Health Outcome and Reduced Incidence with Zoledronic Acid One Yearly (HORIZON) Pivotal Fracture Trial and the HORIZON Recurrent Fracture Trial. SETTING: Multicenter, randomized, double‐blind, placebo‐controlled trials. PARTICIPANTS: Postmenopausal women (aged ≥75) with documented osteoporosis ( T ‐score ≤−2.5 at femoral neck or ≥1 prevalent vertebral or hip fracture) or a recent hip fracture. INTERVENTION: Patients were randomized to receive an intravenous infusion of ZOL 5 mg (n=1,961) or placebo (n=1,926) at baseline and 12 and 24 months. MEASUREMENTS: Primary endpoints were incidence of clinical vertebral and nonvertebral and any clinical fracture after treatment. RESULTS: At 3 years, incidence of any clinical, clinical vertebral, and nonvertebral fracture were significantly lower in the ZOL group than in the placebo group (10.8% vs 16.6%, 1.1% vs 3.7%, and 9.9% vs 13.7%, respectively) (hazard ratio (HR)=0.65, 95% confidence interval (CI)=0.54–0.78, P <.001; HR=0.34, 95% CI=0.21–0.55, P <.001; and HR=0.73, 95% CI=0.60–0.90, P =.002, respectively). The incidence of hip fracture was lower with ZOL but did not reach statistical significance. The incidence rate of postdose adverse events were higher with ZOL, although the rate of serious adverse events and deaths was comparable between the two groups. CONCLUSION: Once‐yearly intravenous ZOL 5 mg was associated with a significant reduction in the risk of new clinical fractures (vertebral and nonvertebral) in elderly postmenopausal women with osteroporosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986 · cited 3×
“A once-yearly intravenous infusion of zoledronic acid (ZOL) 5 mg is a more-attractive therapeutic option in the management of osteoporosis than daily, weekly, or even monthly regimens of oral bisphosphonates.(25) Moreover, the use of intravenous ZOL 5 mg in preventing bone loss and reducing the risk of fractures is we…”
BackgroundMethodResultSelf-citationZoledronic Acid and Clinical Fractures and Mortality after Hip Fracture
Lyles, K. W., Colón-Emeric, C. S., Magaziner, J. S., Adachi, J. D., Pieper, C. F., Mautalen, C., Hyldstrup, L., Recknor, C., Nordsletten, L., Moore, K. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa074941 · Cited by 2,003 · cited 5×
“The incidence of postdose symptoms within 3 days of study drug infusion, such as pyrexia, myalgia, and influenza-like illness, were higher with ZOL 5 mg, as reported previously.(25,28) In contrast to the findings reported in the HORIZON Pivotal Fracture Trial,(25,28) the incidence rate of atrial fibrillation events wa…”
MethodResultInfluentialSelf-citationEffect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
Self-citationReginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Self-citationUpdated Data on Proximal Femur Bone Mineral Levels of US Adults
Looker, A. C., Wahner, H. W., Dunn, W. L., Calvo, M. S., Harris, T. B., Heyse, S. P., Johnston Jr, C. C., & Lindsay, R. (1998) · Osteoporosis International · doi:10.1007/s001980050093 · Cited by 1,121 · cited 1×
“All BMD measurements were corrected for any site- and equipment-related differences.(29,30) Changes in bone turnover markers (BTMs; serum b-C-telopeptide (b-CTx), bone-specific alkaline phosphatase (BSAP), and N-terminal propeptide of type I collagen (P1NP) from baseline were assessed in the HORIZON Pivotal Fracture T…”
Methodvan Eijken, M., Tsang, S., Wensing, M., de Smet, P. A. G. M., & Grol, R. P. T. M. (2003) · Drugs & Aging · doi:10.2165/00002512-200320030-00006 · Cited by 184
The contribution of hip fracture to risk of subsequent fractures: data from two longitudinal studies
Col�n-Emeric, C., Kuchibhatla, M., Pieper, C., Hawkes, W., Fredman, L., Magaziner, J., Zimmerman, S., & Lyles, K. W. (2003) · Osteoporosis International · doi:10.1007/s00198-003-1460-x · Cited by 167 · cited 1×
“It is not only a marker of prevalent osteoporosis but also a precipitant of functional and bone density decline, which further increases fall and fracture risk.(14) Several studies have shown a significant relationship between increasing age and decreasing likelihood of receiving effective osteoporosis treatment.”
BackgroundSelf-citationPatient Adherence to Osteoporosis Medications: Problems, Consequences and Management Strategies
Papaioannou, A., Kennedy, C. C., Dolovich, L., Lau, E., & Adachi, J. D. (2007) · Drugs & Aging · doi:10.2165/00002512-200724010-00003 · Cited by 151
Cited by
The clinician's guide to prevention and treatment of osteoporosis
LeBoff, M. S., Greenspan, S. L., Insogna, K. L., Lewiecki, E. M., Saag, K. G., Singer, A. J., & Siris, E. S. (2022) · Osteoporosis International · doi:10.1007/s00198-021-05900-y · Cited by 1,487
Qaseem, A., Forciea, M. A., McLean, R. M., Denberg, T. D., & for the Clinical Guidelines Committee of the American College of Physicians* (2017) · Annals of Internal Medicine · doi:10.7326/m15-1361 · Cited by 676
Ayers, C., Kansagara, D., Lazur, B., Fu, R., Kwon, A., & Harrod, C. (2023) · Annals of Internal Medicine · doi:10.7326/m22-0684 · Cited by 282
Jobke, B., Milovanovic, P., Amling, M., & Busse, B. (2014) · Bone · doi:10.1016/j.bone.2013.10.024 · Cited by 123
“Bisphosphonates (BP) as a treatment for osteoporosis have been in clinical use for over two decades and proven to be effective in fracture prevention [1–3].”
BackgroundSieber, P., Lardelli, P., Kraenzlin, C. A., Kraenzlin, M. E., & Meier, C. (2013) · Clinical Drug Investigation · doi:10.1007/s40261-012-0041-1 · Cited by 49
Metadata
- Authors
- Boonen, S., Black, D. M., Colón‐Emeric, C. S., Eastell, R., Magaziner, J. S., Eriksen, E. F., Mesenbrink, P., Haentjens, P., & Lyles, K. W.
- Venue
- Journal of the American Geriatrics Society
- Publisher
- Wiley
- Published
- 2010-01-27
- Volume
- 58
- Issue
- 2
- Pages
- 292-299
- ISSN
- 0002-8614 (ISSN-L)
- 1532-5415
- OpenAlex
- W1634061676
- Cited by
- 134
- References
- 9
- FWCI
- 12.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and Safety of a Once‐Yearly Intravenous Zoledronic Acid 5 mg for Fracture Prevention in Elderly Postmenopausal Women with Osteoporosis Aged 75 and Older. https://app.cochat.ai/papers/10.1111/j.1532-5415.2009.02673.x
- The paper
- Boonen, S., Black, D. M., Colón‐Emeric, C. S., Eastell, R., Magaziner, J. S., Eriksen, E. F., Mesenbrink, P., Haentjens, P., & Lyles, K. W. (2010). Efficacy and Safety of a Once‐Yearly Intravenous Zoledronic Acid 5 mg for Fracture Prevention in Elderly Postmenopausal Women with Osteoporosis Aged 75 and Older. Journal of the American Geriatrics Society. https://doi.org/10.1111/j.1532-5415.2009.02673.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.